Important Updates from WCLC 2026

1. DESTINY-Lung04 — 1L trastuzumab deruxtecan in HER2-mutant NSCLC
2. HARMONi-2 — ivonescimab vs pembrolizumab in 1L PD-L1-positive advanced NSCLC
3. REZILIENT 3 — zipalertinib + chemotherapy in EGFR exon 20 insertion NSCLC
4. PAPILLON — final OS with amivantamab + chemotherapy in EGFR exon 20 insertion NSCLC
5. ADAURA — 8-year update of adjuvant osimertinib
6. ARROS-1 — zidesamtinib in ROS1-positive NSCLC
7. MAVERICK / SWOG S1827 — MRI surveillance vs PCI in SCLC
8. ARTEMIS-008 — risvutatug rezetecan vs topotecan in relapsed SCLC
9. TAISHAN-302 — tambotatug pelitecan vs topotecan in relapsed SCLC
10. Tarlatamab program — DeLLphi-309 / DeLLphi-308
11. EVOKE-03 / KEYNOTE-D46 — sacituzumab govitecan + pembrolizumab in PD-L1 ≥50% NSCLC

Taher Abu Hejleh